Multi-center research study illustrates how ogm can potentially result in more patients qualifying for treatments in leukemia

San diego, dec. 09, 2022 (globe newswire) -- bionano genomics, inc. (nasdaq: bngo) today announced the publication of a multi-institutional peer-reviewed study initiated by the cancer genomics consortium evaluating the performance of optical genome mapping (ogm) for detection of cytogenetic abnormalities in acute myeloid leukemia (aml) samples. ogm identified structural variants (svs) and copy number variants (cnvs) with 100% concordance to traditional cytogenetic methods, added important pathogenic findings in 13% of findings, and uncovered additional genomic events in 12% of samples that may change risk stratification and alter recommended clinical care, including access to clinical trials.
BNGO Ratings Summary
BNGO Quant Ranking